secwatch.observer — SEC 8-K summary
======================================

Issuer:     LB PHARMACEUTICALS INC (LBRX)
CIK:        0001691082
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001193125-26-099419
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LB Pharmaceuticals appoints Dr. Robert Lenz to Board and promotes Gad Soffer to COO
--------------------------------------------------------------------------------

- Robert Lenz, M.D., Ph.D., appointed to Board as Class I director; brings over 20 years of neuroscience R&D experience.
- Lenz receives $40,000 annual retainer, $5,000 for Nominating Committee, and initial option grant of 20,000 shares.
- Gad Soffer promoted from Chief Business Officer to Chief Operating and Business Officer, effective March 4, 2026.
- Soffer's annual base salary increased to $505,000 with target bonus of 40% of base salary.
- Lenz previously served as EVP R&D at Neumora Therapeutics and SVP Global Development at Amgen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1691082/000119312526099419/0001193125-26-099419-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1691082/000119312526099419/d181430d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-099419

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer